{"schema_version":"secwatch.filing_event.v1","accession":"0000879169-23-000038","form_type":"8-K","ticker":"INCY","cik":"0000879169","company_name":"INCYTE CORP","filed_at":"2023-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.222004+00:00","generated_at":"2026-06-09T05:19:20.709988+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Incyte Q3 2023 revenues up 12% to $919M; Jakafi guidance tightened to $2.59-2.62B","bullets":["Total GAAP revenues of $919M (+12% YoY); GAAP net income $171M ($0.76 diluted EPS).","Jakafi net product revs $636M (+3% YoY); Opzelura $92M (+141% YoY) on AD/vitiligo demand.","Non-GAAP diluted EPS $1.10 vs $0.60 in Q3 2022; operating income up 63% to $273M.","FY 2023 Jakafi guidance tightened to $2.59-2.62B from $2.58-2.63B; other guidance unchanged.","Phase 2 povorcitinib in prurigo nodularis met primary endpoint; Phase 3 planned for 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000879169-23-000038","json":"https://secwatch.observer/filing/0000879169-23-000038.json","markdown":"https://secwatch.observer/filing/0000879169-23-000038.md","text":"https://secwatch.observer/filing/0000879169-23-000038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879169/000087916923000038/0000879169-23-000038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879169/000087916923000038/incy-20231031.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T05:19:20.709988+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"88d52e00e0b4938cd009b53892e3d75dd9a23c27","claim":"INCYTE CORP reported third fiscal quarter ended September 30, 2023 results: revenue $919 million. Guidance reaffirmed.","evidence_excerpt":"Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs – Total revenues of $919 million in the third quarter (Q3'23)","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/879169/000087916923000038/0000879169-23-000038-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third fiscal quarter ended September 30, 2023"},{"label":"Revenue","value":"$919 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}